FDA
-
-
-
-
-
-
-
Nexalin Technology receives U.S. patent for neurostimulation method
-
-
-
-
-
-
-
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
-
-
-
-
-
-
-
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
-
-
-
-
-
-
-
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
-
-
-
-
-
-
-
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
-
-
-
-
-
-
331,502 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

